This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermann, C.
Right arrow Articles by Hartung, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermann, C.
Right arrow Articles by Hartung, T.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2002, p. 1603-1609, Vol. 40, No. 5
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.5.1603-1609.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparison of Eleven Commercial Tests for Chlamydia pneumoniae-Specific Immunoglobulin G in Asymptomatic Healthy Individuals

Corinna Hermann,1 Kathrin Graf,1 Annemarie Groh,2 Eberhard Straube,2 and Thomas Hartung1*

Biochemical Pharmacology, University of Konstanz, Konstanz,1 Microbiology, University of Jena, Jena, Germany2

Received 14 November 2001/ Returned for modification 2 February 2002/ Accepted 13 February 2002

The seroprevalence of anti-Chlamydia pneumoniae-specific immunoglobulin G (IgG) antibodies is high in the adult population. Experience is required to perform a microimmunofluorescence test (MIF), the current "gold standard" for serological diagnosis, and the assay still lacks standardization. Partially automated enzyme-linked immunosorbent assays (ELISAs) and enzyme immunoassays (EIAs), which are more standardized and for which the reading of results is less subjective, have been developed. The different commercially available serological tests differ in their sensitivities and specificities, depending primarily on the antigen used. Therefore, we evaluated 11 different tests (10 were species specific, 1 was genus specific) for IgG antibodies using serum samples of 80 apparently healthy volunteers. The interpretation of the results was based on the results of the gold standard, MIF: a sample was judged positive if it was positive by at least three of the four different MIFs. Based on this internal standard, we found that 71% of the samples were positive, while 8% were false positive by some tests. The correlations between the results of the different MIFs ranged from 83 to 99%, and the correlations between the results of the MIFs and the different ELISAs and EIAs ranged from 78 to 98%. Comparison of the IgG titers measured by MIF showed good agreement (r = 0.76 to 0.91). This analysis revealed that some ELISAs and EIAs fail to detect low IgG titers. The specificities of the species-specific tests varied from 95 to 100%, and the sensitivities varied from 58 to 100%. These results indicate that serological assays for the detection of anti-C. pneumoniae-specific IgG vary greatly in their sensitivities and specificities. MIF must still be considered the best method for the detection of IgG in apparently healthy subjects, but the sensitivities and specificities of new ELISAs approximate those of MIFs.

* Corresponding author. Mailing address: Biochemical Pharmacology, University of Konstanz, 78457 Konstanz, Germany. Phone: 49-7531-884116. Fax: 49-7531-884117. E-mail: Thomas.Hartung{at}uni-konstanz.de.

Journal of Clinical Microbiology, May 2002, p. 1603-1609, Vol. 40, No. 5
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.5.1603-1609.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Bunk, S., Susnea, I., Rupp, J., Summersgill, J. T., Maass, M., Stegmann, W., Schrattenholz, A., Wendel, A., Przybylski, M., Hermann, C. (2008). Immunoproteomic Identification and Serological Responses to Novel Chlamydia pneumoniae Antigens That Are Associated with Persistent C. pneumoniae Infections. J. Immunol. 180: 5490-5498 [Abstract] [Full Text]  
  • Paldanius, M., Bloigu, A., Alho, M., Leinonen, M., Saikku, P. (2005). Prevalence and Persistence of Chlamydia pneumoniae Antibodies in Healthy Laboratory Personnel in Finland. CVI 12: 654-659 [Abstract] [Full Text]  
  • Maraha, B., den Heijer, M., Kluytmans, J., Peeters, M. (2004). Impact of Serological Methodology on Assessment of the Link between Chlamydia pneumoniae and Vascular Diseases. CVI 11: 789-791 [Abstract] [Full Text]  
  • Hermann, C., Gueinzius, K., Oehme, A., von Aulock, S., Straube, E., Hartung, T. (2004). Comparison of Quantitative and Semiquantitative Enzyme-Linked Immunosorbent Assays for Immunoglobulin G against Chlamydophila pneumoniae to a Microimmunofluorescence Test for Use with Patients with Respiratory Tract Infections. J. Clin. Microbiol. 42: 2476-2479 [Abstract] [Full Text]  
  • Hoymans, V. Y., Bosmans, J. M., Van Renterghem, L., Mak, R., Ursi, D., Wuyts, F., Vrints, C. J., Ieven, M. (2003). Importance of Methodology in Determination of Chlamydia pneumoniae Seropositivity in Healthy Subjects and in Patients with Coronary Atherosclerosis. J. Clin. Microbiol. 41: 4049-4053 [Abstract] [Full Text]  
  • Klein, M., Kotz, A., Bernardo, K., Kronke, M. (2003). Detection of Chlamydia pneumoniae-Specific Antibodies Binding to the VD2 and VD3 Regions of the Major Outer Membrane Protein. J. Clin. Microbiol. 41: 1957-1962 [Abstract] [Full Text]  
  • Portig, I., Goodall, J. C., Bailey, R. L., Gaston, J. S. H. (2003). Characterization of the Humoral Immune Response to Chlamydia Outer Membrane Protein 2 in Chlamydial Infection. CVI 10: 103-107 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»